Related references
Note: Only part of the references are listed.Peptide Epitope Identification by Affinity Selection on Bacteriophage MS2 Virus-Like Particles
Bryce Chackerian et al.
JOURNAL OF MOLECULAR BIOLOGY (2011)
For Cancers Caused by HPV, Two Vaccines Were Just the Beginning
Judy Peres
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2
Ebenezer Tumban et al.
PLOS ONE (2011)
Thermal Stability of RNA Phage Virus-Like Particles Displaying Foreign Peptides
Jerri C. Caldeira et al.
JOURNAL OF NANOBIOTECHNOLOGY (2011)
Versatile Virus-Like Particle Carrier for Epitope Based Vaccines
Alain C. Tissot et al.
PLOS ONE (2010)
Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection
Subhashini Jagu et al.
VACCINE (2010)
Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7
Jerri do Carmo Caldeira et al.
VACCINE (2010)
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years
Cosette M. Wheeler et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
Darron R. Brown et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines
Subhashini Jagu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Role of Heparan Sulfate in Attachment to and Infection of the Murine Female Genital Tract by Human Papillomavirus
Katherine M. Johnson et al.
JOURNAL OF VIROLOGY (2009)
Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines
Christina Schellenbacher et al.
JOURNAL OF VIROLOGY (2009)
Two Highly Conserved Cysteine Residues in HPV16 L2 Form an Intramolecular Disulfide Bond and Are Critical for Infectivity in Human Keratinocytes
Samuel K. Campos et al.
PLOS ONE (2009)
Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes
Kazunari Kondo et al.
JOURNAL OF MEDICAL VIROLOGY (2008)
Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2
David S. Peabody et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2
Hannah H. Alphs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A protective and broadly cross-neutralizing epitope of human papillomavirus L2
Ratish Gambhira et al.
JOURNAL OF VIROLOGY (2007)
Antibodies from women immunized with Gardasil® cross-neutralize HPV 45 pseudovirions
Judith F. Smith et al.
HUMAN VACCINES (2007)
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan
Jeffrey N. Roberts et al.
NATURE MEDICINE (2007)
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11
Katharina Slupetzky et al.
VACCINE (2007)
Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV 16 minor capsid protein L2 surface region
Kazunari Kondo et al.
VIROLOGY (2007)
Modified Tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications
Mark L. Smith et al.
VIROLOGY (2006)
Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
DM Harper et al.
LANCET (2006)
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2
DV Pastrana et al.
VIROLOGY (2005)
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
LL Villa et al.
LANCET ONCOLOGY (2005)
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
DM Harper et al.
LANCET (2004)
Efficient intracellular assembly of papillomaviral vectors
CB Buck et al.
JOURNAL OF VIROLOGY (2004)
Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers
K Kawana et al.
VACCINE (2003)
Epidemiologic classification of human papillomavirus types associated with cervical cancer
N Muñoz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Human papillomavirus and cervical cancer
EM Burd
CLINICAL MICROBIOLOGY REVIEWS (2003)
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes
RBS Roden et al.
VIROLOGY (2000)
Share Paper
